bioMerieux (BIM) AI Stock Analysis

• Market Cap: €14.00B
• Dividend Yield: 0.76%
• Average Volume (3M): 110.32K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.63
• Revenue Growth: 8.31%
• EPS Growth: 21.00%
• Country: FR
• Employees: 14,147
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.84
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 114,430
• 30 Day Avg. Volume: 110,320
• PEG Ratio: 6.26
• Price to Book (P/B): 3.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 43.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €128.50
• Price Target Upside: 8.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 72 Outperform
• Price Target: €131.00 ▲(10.64%Upside)

The overall stock score reflects bioMerieux's strong financial performance, which is the most significant factor. However, the technical analysis suggests neutral sentiment, and the valuation indicates potential overvaluation, which moderate the overall score.

Positive Factors

Guidance Increase

Full-year guidance was uplifted from 6-8% to 8-10% organic sales growth.

Organic Growth

Organic growth for the quarter was 10.3%, surpassing the consensus expectation of 8.4%.

Product Launches

New product launches like SPOTFIRE, VITEK, and VIDAS approvals are driving in-market traction.

Negative Factors

Installed Base Growth

BIOFIRE installed base growth slowdown may be debated.

Product Segment Performance

Immunoassays are still weighed down by the decrease in procalcitonin tests.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux (BIM) is a global leader in the field of in vitro diagnostics, headquartered in Marcy-l'Étoile, France. The company specializes in providing diagnostic solutions for medical and industrial applications, focusing on areas such as clinical diagnostics, microbiology, immunoassays, and molecular biology. bioMérieux offers a comprehensive range of products and services, including diagnostic tests, reagents, instruments, and software, aimed at improving patient care and enhancing public health.

How the Company Makes Money

bioMérieux generates revenue primarily through the sale of its diagnostic tests and instruments to healthcare institutions, laboratories, and industrial companies worldwide. Key revenue streams include clinical applications, which provide tests for infectious diseases, cancer, cardiovascular diseases, and other medical conditions. Additionally, the company offers industrial applications that deliver testing solutions for food, pharmaceutical, and cosmetic production to ensure safety and quality. bioMérieux's earnings are further bolstered by service contracts, maintenance agreements, and the sale of consumable reagents required for its diagnostic instruments. The company's global reach and strategic partnerships with healthcare providers, research institutions, and industry leaders also play a crucial role in its financial success.

bioMerieux Financial Statement Overview

Summary

bioMerieux is in a strong financial position with consistent revenue and profit growth, solid margins, and effective cash flow management. The balance sheet reflects low leverage and robust equity, indicating financial stability. However, there is room for improvement in return on equity.

Income Statement

bioMerieux has demonstrated strong and consistent revenue growth, with a notable increase of approximately 8.3% from 2023 to 2024. The gross profit margin stands at 55.7%, reflecting effective cost management. The net profit margin is 10.9%, which is solid for the industry. EBIT and EBITDA margins are healthy at 14.8% and 22.5%, respectively, indicating robust operational efficiency.

Balance Sheet

The company exhibits a strong equity base with an equity ratio of 72.9%, indicating financial stability. The debt-to-equity ratio is low at 0.12, suggesting prudent leverage management. The return on equity is 10.3%, which is respectable, though there is room for improvement in generating higher returns on equity.

Cash Flow

bioMerieux's free cash flow has seen significant growth, increasing from €107.1 million in 2023 to €321.5 million in 2024. The operating cash flow to net income ratio is robust at 1.54, showing strong cash conversion from earnings. The free cash flow to net income ratio is 0.74, indicating effective cash generation relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.98B	3.67B	3.59B	3.38B	3.12B
Gross Profit	2.22B	2.06B	1.96B	1.97B	1.74B
EBITDA	897.50M	827.60M	811.90M	977.80M	747.70M
Net Income	432.20M	357.60M	452.40M	601.10M	404.40M
Balance Sheet
Total Assets	5.77B	5.26B	5.19B	4.61B	3.93B
Cash, Cash Equivalents and Short-Term Investments	449.80M	352.40M	552.60M	803.50M	389.20M
Total Debt	490.70M	518.80M	505.40M	462.50M	481.30M
Total Liabilities	1.56B	1.51B	1.54B	1.44B	1.45B
Stockholders Equity	4.20B	3.75B	3.60B	3.11B	2.43B
Cash Flow
Free Cash Flow	321.50M	107.10M	188.40M	534.60M	305.30M
Operating Cash Flow	667.30M	445.40M	475.10M	824.70M	582.80M
Investing Cash Flow	-359.80M	-488.80M	-528.10M	-307.30M	-266.00M
Financing Cash Flow	-212.60M	-122.30M	-244.20M	-140.60M	-175.40M

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 118.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Neutral. The current price of 118.4 is below the 20-day moving average (MA) of 119.12, below the 50-day MA of 118.84, and above the 200-day MA of 110.95, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 46.77 is Neutral, neither overbought nor oversold. The STOCH value of 30.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERF	74 Outperform	€11.18B	28.78	9.66%	0.98%	6.70%	32.29%
BIM	72 Outperform	€14.00B	32.30	10.86%	0.76%	8.31%	21.00%
SAN	71 Outperform	$101.37B	18.71	7.34%	4.72%	-4.62%	2.88%
DIM	62 Neutral	€18.53B	90.66	5.24%	0.36%	5.21%	-23.23%
ALERS	61 Neutral	€254.64M	63.83	2.27%	―	18.89%	-20.75%
Sector *	52 Neutral	$7.35B	-0.07	-63.71%	2.36%	16.17%	0.03%

bioMerieux Corporate Events

bioMérieux’s VITEK® COMPACT PRO Gains FDA Approval to Combat Antibiotic Resistance

bioMérieux has received 510(k) authorization from the FDA for its VITEK® COMPACT PRO system, designed to enhance the identification of microorganisms and antibiograms in both clinical and industrial settings. This system aims to address the growing challenge of antibiotic resistance by providing rapid, accurate diagnostics, improving laboratory efficiency, and promoting the proper use of antibiotics. The VITEK® COMPACT PRO is set to launch globally in 2025, offering advanced ergonomics and automation to small and medium-sized laboratories, thus strengthening bioMérieux’s position as a leader in microbiology innovation.